Sinofn Health
Sinofn Health
In the competitive global nutraceutical market, differentiating your brand requires more than just generic formulations. At SINOFN, we leverage our deep-rooted partnership with the Chinese Academy of Sciences (CAS) to transform the landscape of Custom Private Label Probiotics. Our philosophy centers on "Information Gain"—providing our clients with the scientific leverage needed to dominate market segments, from gut-health optimization to cognitive performance enhancers.
Modern consumers demand hyper-personalized solutions. Our R&D team segments probiotic formulations into specific lifestyle and physiological application scenarios:
Our manufacturing technology roadmap is designed to solve the perennial challenge of probiotics: Stability. We employ advanced microencapsulation technologies that ensure shelf-stability without compromising enteric release. Our facility, established in 2025, utilizes AI-driven stability chambers to predict long-term efficacy, ensuring that your private label product hits the market with the highest Colony Forming Unit (CFU) integrity.
Choosing a Chinese manufacturing partner is no longer just about cost; it is about strategic supply chain resilience. SINOFN integrates blockchain-based batch tracking from raw material intake to final packaging. Our industrial status allows us to mitigate logistics volatility, ensuring that global brands receive consistent, high-grade ingredients even amidst global supply chain disruptions. We don't just "fill capsules"; we orchestrate a seamless industrial ecosystem.
Mrs. GuoHong Liu founded SINOFN in 2012, inspired by clinical work with PKU patients. Her mission remains the bedrock of our operations: "We measure success not just in revenue, but in lives improved through accessible science."
Led by Dr. Zhang Ying (CAS Associate Researcher) and Dr. Tan Shengjie (Peking University Medical Doctor), our team ensures that every formulation is backed by peer-reviewed research and clinical validation.
For standard white-label, it is 4-6 weeks. For custom R&D formulations involving new strain stabilization, we typically engage in a 12-week development cycle including pilot-scale prototyping.
Our facility is ISO 22000, HACCP, and FSSC 22000 certified. We maintain an active dossier for FDA registration in the US and EU compliance standards, ensuring your products can cross borders seamlessly.
Yes. Our "Innovation-First" line is designed for scaling brands, providing flexible MOQs while maintaining the high quality of our industrial-scale lines.
